Looking forward, the company must show that it has a business plan for future growth in order to garner new investor interest. More then a year ago, investors were told that the company intended to file at least one ANDA and expected one approval each quarter.
A year ago, due to the delay in approval of the Adderall ER, the company had to cease R&D as cash on hand and inability to access funds from Lincoln Park threatened bankruptcy causing the auditors to issue a going concern caveat.
I share your disappointment that NH chose to divest 4 opioid drugs, which cost millions to develop, for chump change. The excuse given that the company needed to get under the FDA quota imposed for too many products seemed lame at best.
Likewise, the Mikah deal for the Sungen share of the Adderall product should be revealed or at least the company should give shareholders an idea of what the future plan is for their most important product.
NH has 3 weeks to produce some meaningful news before the next conference call.
Market Data 
Markets 
AI
